Journal article

Immunogenicity study of engineered ferritins with C- and N-terminus insertion of Epstein-Barr nuclear antigen 1 epitope

Yiran Qu, Bingyang Zhang, Yingli Wang, Shuang Yin, Jordan L Pederick, John B Bruning, Yan Sun, Anton Middelberg, Jingxiu Bi

VACCINE | ELSEVIER SCI LTD | Published : 2021


Human ferritin heavy chain, an example of a protein nanoparticle, has recently been used as a vaccine delivery platform. Human ferritin has advantages of uniform architecture, robust thermal and chemical stabilities, and good biocompatibility and biodegradation. There is however a lack of understanding about the relationship between insertion sites in ferritin (N-terminus and C-terminus) and the corresponding humoral and cell-mediated immune responses. To bridge this gap, we utilized an Epstein-Barr Nuclear Antigen 1 (EBNA1) epitope as a model to produce engineered ferritin-based vaccines E1F1 (N-terminus insertion) and F1E1 (C-terminus insertion) for the prevention of Epstein-Barr virus (EB..

View full abstract

University of Melbourne Researchers


Funding Acknowledgements

This work was supported by the University of Adelaide's DVCR-Bioprocess Facility Fund-2018. We acknowledge Shanxi Education Science "1331 project"special research project (Research and Development of Traditional Chinese Medicine Micro-emulsion and New Biological Preparation), and also thank Adelaide Microscopy Center for assisting to access the transmission electron microscopy. This research was undertaken on the MX1 beamline at the Australian Synchrotron, part of ANSTO.